Regeneron
Regeneron is a New York-based biotechnology company with revenues in excess of $12 billion. It offers products to help patients battling cancer, eye diseases, arthritis, skin conditions and infectious diseases.
Latest
Stock drama, cancer vaccine success, and new science — highlights from AACR
STAT Plus: The biotech scorecard for the second quarter: 24 stock-moving events to watch
Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster
STAT Plus: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’
STAT Plus: Still hoping for looser FDA rules, Regeneron says it will test durable antibody for Covid
STAT Plus: Regeneron’s Eylea sales dip, as competition looms
STAT Plus: Inflation caused another big drop in net drug prices, analysis finds
All Coverage
advertisement
